Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 6:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,580 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Results available

Effect of Diabetes Mellitus on Cholesterol Metabolism

NCT00879710
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Hypercholesterolemia
Interventions
simvastatin or ezetimibe
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Type 1 Diabetes Mellitus
Interventions
LY2605541, Insulin Glargine
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Type 1 Diabetes
Interventions
High fat meal
Other
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Diabetes Mellitus, Type 1
Interventions
Diabetes Assistant (DiAs) with USS Virginia, Sensor Augmented Pump Therapy
Device · Other
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 35 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Stanford, California • Charlottesville, Virginia
Conditions
Type 2 Diabetes
Interventions
Acipimox, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Diabetes Mellitus, Type 1
Interventions
18F-FP-DTBZ (18F-AV-133), Arginine-hydrochloride
Drug · Biological
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Type 1 Diabetes
Interventions
Questionnaires
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
9 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Completed Not applicable Interventional Results available

Glucose Counterregulation in Long Standing Type 1 Diabetes

NCT01474889
Conditions
Hypoglycemia Unawareness, Type 1 Diabetes, Healthy
Interventions
RT-CGM
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
25 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Conditions
Diabetes Mellitus, Type 1
Interventions
Placebo and Insulin monotherapy via CL, Sitagliptin and insulin/novolog via CL
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
14 Years to 30 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Type1diabetes, Low Carbohydrate Diet
Interventions
low carbohydrate diet, standard carbohydrate diet
Other
Lead sponsor
Yale University
Other
Eligibility
12 Years to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Type 1 Diabetes Mellitus
Interventions
CareSens Air 3 primary insertion, CareSens Air 3 secondary insertion
Device
Lead sponsor
i-SENS, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
Escondido, California • Walnut Creek, California • Atlanta, Georgia + 1 more
Conditions
Diabetes Mellitus, Type 1
Interventions
Artificial Pancreas
Device
Lead sponsor
University of Virginia
Other
Eligibility
14 Years to 74 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Santa Barbara, California • Stanford, California • Aurora, Colorado + 4 more
Conditions
Diabetes Mellitus, Type 1
Interventions
Bright 1 Bodies
Behavioral
Lead sponsor
Yale University
Other
Eligibility
11 Years to 19 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Not applicable Interventional Results available

Continue Glucose Monitoring Before Insulin Pump

NCT02813421
Conditions
Type 1 Diabetes Mellitus
Interventions
CGM Informed
Device
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
2 Years to 24 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Type 1 Diabetes
Interventions
Thiazolidinedione
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Type 1 Diabetes
Interventions
Mini-glucagon, Remote monitoring, Carbohydrates
Drug · Device · Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
7 Years to 21 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Stanford, California
Completed Phase 2Phase 3 Interventional Results available

Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes

NCT03046927
Conditions
Type 1 Diabetes
Interventions
Ergocalciferol, Placebo
Drug · Other
Lead sponsor
Benjamin U. Nwosu, MD
Other
Eligibility
10 Years to 21 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Type 1 Diabetes
Interventions
DailyDose Decision Support
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Diabetes type1
Interventions
AG019 - Low Dose, Teplizumab, Placebo-AG019, Placebo-Teplizumab, AG019 - High Dose
Biological · Drug
Lead sponsor
Precigen Actobio T1D, LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • Ventura, California + 12 more
Conditions
Type 1 Diabetes
Interventions
Diabetes Strengths Study
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogeneic Pancreatic Islet Cells, Antithymocyte Globulin, Sirolimus, Tacrolimus, Etanercept, Islet Transplantation, Basiliximab
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
7
States / cities
San Francisco, California • Miami, Florida • Atlanta, Georgia + 3 more
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogenic islet cells (human, U. Chicago), Intraportal infusion of islet cells
Biological · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 68 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
ECHO Tele-Education
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
32,796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
17
States / cities
Davis, California • Fresno, California • Multiple Locations, California + 11 more
Conditions
Islet Transplantation in Diabetes Mellitus Type 1
Interventions
Reparixin, Placebo
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chicago, Illinois